Renal Cancer News

Excess Body Weight Linked with More Than 100,000 New Cancer Diagnoses Each Year in U.S. (November 9, 2009)

According to estimates from the American Institute for Cancer Research (AICR), excess body weight may be responsible for more than 100,000 new cancer diagnoses each year in the United States. Excess body weight is increasingly recognized as a risk factor... Continue Reading

Addition of Low-dose Interferon Alfa to Nexavar© Does Not Improve Kidney Cancer Outcomes (November 3, 2009)

In a Phase II clinical trial, the combination of low-dose interferon alfa and Nexavar® (sorafenib) did not appear to be any more effective than Nexavar alone for the treatment of metastatic renal cell (kidney) cancer. These results were published in... Continue Reading

Broad Range of Patients with Renal Cell Carcinoma Benefit from Sutent (September 11, 2009)

Sutent® (sunitinib) is safe and effective for a broad population of patients with metastatic renal cell carcinoma, according to the results of a trial published in Lancet Oncology.[1] The kidneys are each filled with tiny tubules that clean and filter... Continue Reading

Avastin® Approved for Kidney Cancer (August 6, 2009)

The U.S. Food and Drug Administration (FDA) has expanded the approval of the targeted therapy Avastin® (bevacizumab) to include treatment of metastatic renal cell carcinoma (kidney cancer). The approval for kidney cancer specified that Avastin be used... Continue Reading

Afinitor® Effective Against Metastatic Kidney Cancer (May 18, 2009)

According to the results of a Phase II clinical trial, roughly 70% of patients with metastatic renal cell (kidney) cancer experienced either a reduction in detectable cancer or stable disease following treatment with Afinitor® (everolimus). These... Continue Reading

Nexavar® Is Better Tolerated than Interferon in Patients with Metastatic Renal Cell Carcinoma (March 31, 2009)

In patients with untreated renal cell cancer (RCC), Nexavar® (sorafenib) results in a similar progression-free survival (PFS) to interferon, yet patients experience greater rates of tumor shrinkage and report a better quality of life (QOL) with Nexavar... Continue Reading

Afinitor® Approved for Advanced Kidney Cancer (March 31, 2009)

The U.S. Food and Drug Administration has approved Afinitor® oral tablets (everolimus) for the treatment of patients with advanced renal cell carcinoma that has progressed after treatment with Sutent® (sunitinib) or Nexavar® (sorafenib). The kidneys... Continue Reading

Meat, Fat, and Protein Consumption Does Not Increase Risk of Renal Cell Cancer (January 14, 2009)

Meat, Fat, and Protein Consumption Does Not Increase Risk of Renal Cell Cancer Intake of red meat, processed meat, poultry, or seafood is not associated with a risk of renal cell cancer, according to the results of a study published in the Journal of... Continue Reading

Cardiac Toxicity in Patients with Metastatic Renal Cell Carcinoma Receiving Tyrosine Kinase Inhibitors (November 12, 2008)

Cardiac Toxicity in Patients with Metastatic Renal Cell Carcinoma Receiving Tyrosine Kinase Inhibitors In a recent single-center study, researchers analyzed the cardiac toxicity associated with the tyrosine kinase inhibitors Sutent® (sunitinib) and Nexavar®... Continue Reading

Nexavar® Effective in Elderly Patients with Kidney Cancer (October 22, 2008)

Nexavar® Effective in Elderly Patients with Kidney Cancer Nexavar (sorafenib) provides an effective and safe treatment option for elderly patients with renal cell carcinoma (RCC), or kidney cancer. These results were recently published in the Journal... Continue Reading